


How can I get an MMprofiler™ test in this hospital?

Take this leaflet to your doctor who can explain how the test works and if it would be appropriate for you.

In the UK, the MMprofiler™ is provided through our exclusive partner Everything Genetic, which has special arrangements with many private healthcare providers. Today many private insurers in the UK also believe in this targeted patient testing approach and are therefore reimbursing the cost of the MMprofiler™ test – check with your provider.

Doctors go to:

everythinggeneticltd.co.uk
– or call one of our experts on 01270 623179



MMprofiler™

product from SkylineDx

SkylineDx is a high-tech biotech company specialising in oncology, particularly blood cancers. It works with academic, pharmaceutical, and industrial partners for the development and commercialisation of diagnostic tests based on genetics.

The company is headquartered in the Netherlands and has a commercial office and laboratory in the USA. Its exclusive partner™ in the UK is Everything Genetic Ltd.



Everything Genetic Ltd is the exclusive distributor for SkylineDx in the UK.

www.everythinggeneticltd.co.uk

Tel: 01270 623179

MMprofiler™

Multiple myeloma
– helping your doctor
select the best treatment
plan for you

No two cancer cells are
alike – find out about
personalised therapy

Distributed by



Learn more about your disease and treatment options

Recent advances mean that the blood cancer multiple myeloma (MM) is now considered very treatable, although it cannot usually be cured. Whilst traditional treatments such as chemotherapy and autologous bone marrow transplantation remain important, newer targeted drugs such as lenalidomide, bortezomib and daratumumab have had a significant impact.

The clinical course of myeloma varies a lot between different people. This variability is related to unique properties of your cancer cells. If you have just been diagnosed (or are suffering a relapse), there are tools available to help you and your doctor understand how your myeloma will behave – whether the cancer is likely to grow quickly or slowly. One such tool is MMprofiler™.



What do people say?

“SkylineDx... developed and validated a diagnostic device called the MMprofiler™ which can determine the risk of a myeloma patient... This classification is done using gene expression profiling (GEP), a technology in which the activity (or ‘expression’) of specific genes is measured in tissue samples – creating a patient specific picture. The GEP of an individual patient, represents their biology and can give important clues on response to drugs”.

Myeloma Patient Europe (MPE)

“Patients are less likely to get over- or undertreatment because the risk profile is measured much more accurately which is an enormous gain.”

Hans Scheurer (MM patient and chairman MPE)

“The MUK nine trial will give patients access to innovative new treatment and state-of-the-art molecular testing [MMprofiler™, red]. We hope it will transform myeloma treatment from a one-size fits all approach to a stratified approach driven by disease characteristics”

Dr Kaiser (Chief Investigator for the Myeloma UK nine trial and Senior Researcher at ICR, London)

Guiding selection of the most appropriate treatment for you

For decades, we have known – but were not able to determine why – patients with the same type of cancer experience different responses to the same treatment.

Now, after ground-breaking genetic research, we understand that, like human beings, no two cancers are alike. This means that two patients diagnosed with myeloma may require treatment at different times and may respond to the same treatment in different ways.

The MMprofiler™ is a clinically-proven and reliable prognostic test which measures the activity of 92 genes in the myeloma cells. The results of MMprofiler™ can accurately determine whether your myeloma is low, standard or high risk. This can make a difference to which treatment strategy your doctor decides is the most appropriate for you.

Low, standard or high-risk

Low and standard risk myeloma behave in a less aggressive way. A treatment strategy that is too strong may expose you to unnecessary side effects.

High risk myeloma can be more challenging to treat because it is more aggressive. A different treatment strategy may be required to slow down the progression of the disease.

Knowing your risk classification will help you better understand your myeloma, and better plan for the future. It may also help your doctor select the most appropriate therapy for you.